Ascendis Pharma A/S
TransCon CNP
pediatric achondroplasia
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for TransCon CNP in pediatric achondroplasia are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 15h ago
“Week 78 COACH data update anticipated in second quarter of 2026.”